Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Oxiracetam and Pramiracetam — mechanism, side effects, legal status, and pricing.
Oxiracetam is a non-peptide racetam-class cognitive enhancer, structurally the 4-hydroxy analog of piracetam. It is approved as a prescription drug for dementia in Italy (since 1984) and China, but is NOT FDA-approved in the United States. The FDA has classified oxiracetam as a 'new drug' requiring approval and determined it does not qualify as a dietary supplement; in the US it is sold only as an unregulated gray-market research chemical.
Pramiracetam is a non-peptide synthetic racetam-class nootropic (2-oxopyrrolidone/pyrrolidinone acetamide derivative) with CAS 68497-62-1 and molecular formula C14H27N3O2. It was previously approved and marketed in Italy and some Eastern European countries under brand names Pramistar, Neupramir, and Remen for memory/attention deficits in aging-associated dementias; Italian authorization was revoked in 2020 at manufacturer request. It is not FDA-approved in the United States, where it is sold only as an unapproved gray-market research chemical. The related racetam phenylpiracetam is explicitly listed on the WADA Prohibited List as an S6 stimulant; pramiracetam itself is not explicitly named, leaving its status under WADA's 'similar structure/effect' catch-all unresolved.
Oxiracetam
Pramiracetam
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Oxiracetam
No pricing data yet.
Check Oxiracetam prices →Pramiracetam
No pricing data yet.
Check Pramiracetam prices →COA corpus from Disclosed Labs — independently tested batches only.
Oxiracetam
2
COAs
99.4%
Avg purity
2
Labs
Pramiracetam
2
COAs
99.9%
Avg purity
2
Labs
Multiple placebo-controlled human trials exist in dementia, organic brain syndrome, and traumatic brain injury populations, plus human pharmacokinetic studies. One double-blind controlled trial in elderly organic-brain-syndrome patients used doses titrated from 400–2400 mg/day; a separate placebo-controlled trial in senile dementia of Alzheimer type and multi-infarct dementia used 800 mg twice daily and reported improvement on cognitive measures versus placebo. Preclinical findings include AMPA receptor modulation and enhanced neurotransmitter release in rat hippocampal preparations, and identification of the (S)-enantiomer as the active component alleviating cognitive impairment in a rat chronic cerebral hypoperfusion model. Oral bioavailability in humans is ~56% (versus 28–42% in rats, 81–90% in dogs), with predominantly renal excretion of unchanged drug.
Key references
Human data consist of a handful of small older trials (1985–1996): healthy-volunteer pharmacokinetic studies, a scopolamine-induced-amnesia challenge study, a placebo-controlled trial in young males with head-injury/anoxia-related memory deficits (400 mg TID improved delayed recall), and a small dose-finding trial in Alzheimer's disease that found no convincing benefit at doses up to 4,000 mg. A scopolamine-challenge study (600 mg BID × 10 days) showed partial mitigation of induced amnesia in healthy young and older male volunteers. No modern (post-2000) randomized controlled trials were located. Preclinical findings: in rats, 7.5 and 15 mg/kg/day × 7 weeks significantly improved reference (long-term) memory on a 16-arm radial maze but did not affect working memory; 300 mg/kg i.p. increased cortical nitric oxide synthase activity ~20% (synergistic ~40% increase with lithium pretreatment); moderate protection against hypobaric-hypoxia-induced deficits in immature rats.
Oxiracetam and Pramiracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs